drug adherence

NEW TAIPEI CITY, TAIWAN, April 14, 2026 GlycoNex, Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency...

REDWOOD CITY, CALIFORNIA, USA, April 13, 2026 Revolution Medicines has announced positive topline results from its pivotal Phase 3...

SAN DIEGO, USA, April 14, 2026 Neurocrine Biosciences has presented new real-world evidence (RWE) demonstrating that patients treated with...